Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Gains from Sales and Divestitures (2023 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $269644.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 72.08% to $269644.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $269644.0, a 72.08% decrease, with the full-year FY2025 number at $269644.0, down 72.08% from a year prior.
  • Gains from Sales and Divestitures was $269644.0 for Q4 2025 at Phathom Pharmaceuticals, down from $1.3 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $1.3 million in Q3 2025 to a low of $191526.0 in Q1 2023.
  • A 3-year average of $622506.1 and a median of $423717.5 in 2023 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: skyrocketed 102.78% in 2024, then crashed 72.08% in 2025.
  • Phathom Pharmaceuticals' Gains from Sales and Divestitures stood at $1.0 million in 2023, then decreased by 4.36% to $965881.0 in 2024, then plummeted by 72.08% to $269644.0 in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Gains from Sales and Divestitures are $269644.0 (Q4 2025), $1.3 million (Q3 2025), and $965881.0 (Q4 2024).